Parkinson DiseasePARADIGMNCT05437458
Parkinson's Disease: Risk Assessment of Persistent Delirium and Its Management
An observational study of Parkinson Disease and Delirium in Old Age, run by Newcastle University at 1 site in United Kingdom.
Trial summary
Background: delirium describes the change in people's behaviour and thinking when they are unwell. People with delirium may appear confused, have difficulty with organisation and can be different to their usual personality. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease, Delirium in Old Age
- What is being tested?
- Delirium (exposure)
- How many people
- 217 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Feb 2022to 30 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 1. People aged 65 years or older in 2015, with a diagnosis of idiopathic Parkinson's, who attend the outpatient clinic at Airedale Hospital and have had a hospital admission of at least 24 hours during 2015-2019. 2. A carer (aged 18 years and older) for a person with Parkinson's, who has experienced persistent delirium.
Who may be able to join
- Participants must be aged at least 65 years old in 2015.
- Participants must have a diagnosis of idiopathic Parkinson's disease using Queen's Square Brain Bank criteria (32) diagnosed by a movement disorders expert.
- Admitted patients must have stayed in hospital >24 hours for at least one hospital admission.
- Participants must have had previous admissions/attendance to the hospital between 2015-2019.
- An appropriate consultee must be available and willing to be involved in this study for potential participants without the mental capacity to consent to the extraction of information from their medical records.
- For the qualitative study, participants must have the mental capacity to consent and must have been affected by persistent delirium. The participant must be able to understand, write and speak English.
Show all 10Show fewer
- Participants must be aged 18 or over.
- Participants must have the mental capacity to consent.
- Participants must have been a primary carer for someone living with Parkinson's, who has had a previous experience of persistent delirium, during 2015-2020.
- Participants must be able to understand, write and speak English.
Who cannot join
- Aged less than 65 years old in 2015.
- Diagnosed with drug-induced parkinsonism, vascular parkinsonism, atypical Parkinsonian disorder (e.g. progressive supranuclear palsy, multiple systems atrophy, corticobasal syndrome) or dementia (e.g. dementia with Lewy bodies, vascular dementia, Alzheimer's disease).
- Potential participants will be excluded from the interview if they cannot communicate verbally or cannot read/write in English.
- The potential participant's medical records are incomplete and no alternate strategies are appropriate to account for the missing data, without introducing significant study bias or inaccuracy in statistical findings. Criteria for when the medical records will be excluded in the analysis will be:
- 1. There is uncertainty regarding the identity of the medical records. 2. Documentation for the admission of interest is missing to the extent that researchers are unable to extract the relevant data required for the aims of this study.
- 5) For the qualitative study, potential participants will be excluded if they do not have the mental capacity to consent.
Show all 14Show fewer
- 6) Potential participants without a consultee and also do not have the mental capacity to consent to this study.
- 7) Potential deceased participants will be excluded if there is previous documentation that the person would not have wanted to participate in research studies.
- The potential participant is aged less than 18 years old.
- The potential participant does not have the mental capacity to consent to this study.
- The potential participant is not the primary carer for someone with Parkinson's and has been affected by persistent delirium, during 2015-2020.
- The potential participant does not understand, write and/or speak English.
- The potential participant has a severe speech impairment to the extent that the audio recording of the interview is unintelligible.
- -
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
Airedale Hospital
Keighley, West Yorkshire, BD20 6TD
William Lee, MB/BS, 01535 652511 ext. 5086, william.lee4@nhs.net
William Lee, MB/BS
About this study
Background: delirium describes the change in people's behaviour and thinking when they are unwell. People with delirium may appear confused, have difficulty with organisation and can be different to their usual personality. Older people with Parkinson's are particularly susceptible to persistent delirium, which can last over 14 days. They are more likely to need increased community support and they have a greater risk of death and dementia.
However, there is limited research for people with Parkinson's on how to effectively manage persistent delirium and how to identify those at risk of persistent delirium. Community support may not sufficiently support the care needs of people with Parkinson's, and this is expected to be more detrimental for people also affected by persistent delirium
Read more
Study Design: retrospective case note review with qualitative interviews.
Study participants: older people (≥65 years old) with Parkinson's disease, previously affected by either persistent delirium or another form of delirium (e.g. hyperactive, hypoactive, mixed). 207 participants with Parkinson's for quantitative data collection. The qualitative study will include up to 10 participants with Parkinson's from the quantitative part of this study. An additional maximum of 10 more carers for people with Parkinson's may also be interviewed.
Research Aims:
- To develop and estimate the assessment tool's sensitivity and specificity to predict persistent delirium in older people with Parkinson's in the outpatient setting. Persistent delirium in this study will be initially defined as a delirium lasting ≥14 days. An associated secondary objective will be to develop a scoring system that allocates an increasing number of points to risk factors that have a stronger association for predicting delirium.
- To evaluate the management strategies used for persistent delirium.
- To determine what are the community care needs for people recovering from persistent delirium.
Read the detailed description
Background and Rationale Parkinson's disease is the second most common neurodegenerative condition. Delirium is an acute neuropsychiatric syndrome characterised by an altered level of consciousness, confusion and impaired attention. Usually, delirium is transient if the aetiological factors are corrected or if its effects are minimised by medical treatment. Delirium is potentially preventable in 30-40% of cases, but delirium can result in increased mortality and an increased risk of dementia.
Persistent delirium is when delirium continues to affect patients over weeks to months. However, the exact duration for delirium to be defined as being persistent remains controversial. Previous studies have reported the duration of persistent delirium to be between 7 days to >4 weeks. Persistent delirium in this study will be defined as delirium lasting ≥14 days, which is the average reported by the previous studies. Delirium in older people at the point of hospital discharge is associated with worse outcomes regarding function, cognition, mortality and are more likely to need nursing home placement.
People with Parkinson's could be five times more likely to develop delirium and often delirium in Parkinson's is under-recognised in secondary care.
The use of risk stratification of delirium in people with Parkinson's could highlight the most vulnerable patients so that preventive care can be implemented to minimise their risk of adverse outcomes and complications.
Currently, management strategies for delirium in Parkinson's disease are predominantly based on expert opinion and there is a need for research to determine what are the optimal management strategies for this patient group. Moreover, there are concerns that current community support services do not adequately address the psychosocial issues in older people with advanced Parkinson's disease, which may provide an even greater challenge for patients recovering from persistent delirium.
In summary, older people with Parkinson's are particularly susceptible to delirium, but there is also a paucity of research in this area, which needs to be urgently addressed, to not only prevent the adverse outcomes at an individual level but also the detrimental socio-economic impacts on the wider community.
Participant Recruitment
Eligible potential participants will be invited to the study by their usual medical team during an outpatient Parkinson's clinic at a rural, district general hospital. Eligible potential participants with their permission will be contacted by researchers. Carers of people with Parkinson's will be invited to a qualitative interview. Participants will be recruited consecutively in the order that consent forms were completed till the target sample size has been achieved for the quantitative part of the study. For the qualitative part of the study, recruitment will cease once data saturation has been reached.
Methods
There are 3 main parts to this study:
- Development and testing of an assessment tool for persistent delirium in people with Parkinson's: Participants will be recruited from outpatient clinics for people with Parkinson's this may take up to 8 months. Initially, the potential participant's usual doctor will invite them to take part in the study, before the research team goes through the details of the study with the potential participant. Written informed consent will be needed. If the potential participant cannot consent for themselves, then a consultee will be contacted. A consultee is someone that is well known to the potential participant and is willing to advise on whether the potential participant, should take part in the study. In tandem with participant recruitment for at least 14 months, there will be data collection from medical records. Medical records will be reviewed to identify the characteristics and events that have affected people who then go on to develop persistent delirium. Participants' characteristics that will be analysed will be broadly related to their general level of physical fitness, the severity of their Parkinson's disease, visual or hearing difficulties and any conditions affecting their mind, such as dementia. Events that the medical notes will be checked for include: the medical care, blood tests and imaging that the participant received, any complications during their hospital stay and the support that they received in the community. Participants will be divided into 3 groups: those with persistent delirium, which is where participants become unwell, which has led to the participant becoming confused or have changes in their behaviour for 14 days or more. Another group with non-persistent delirium, this is when the delirium has lasted less than 14 days and a control group who have not had delirium at all. The Chief Investigator will write a summary of each participant but identifiable details will be excluded. These summaries will be reviewed by at least one other medical specialist involved in the care of older people, to double-check that the study findings are as accurate as possible. Potentially, another medical colleague may be required if there is any initial disagreement between specialists. To further confirm the accuracy of the findings, healthcare staff entries in the notes and information collected from relatives/carers can also be used. 8 months will be needed to develop and test the assessment tool. This will be done by using statistical methods, such as logistic regression to determine which of these factors are most strongly linked to persistent delirium. A scoring system can be developed, which allocates an increasing number of points to participants with a risk factor that is more strongly linked to persistent delirium. The accuracy of the tool will be determined by its ability to detect people with delirium (sensitivity) and its ability to detect people without delirium (specificity). It is estimated that 207 participants will be required. This is assuming that persistent delirium is present in approximately 20% of patients. The estimate of persistent delirium is based on local audit data.
- Development of a management plan From the information collected in 1), there will be a review of the care that a participant received to identify factors that helped and hindered their recovery from delirium. This information will allow the Chief Investigator to begin to develop a care plan, which can then be tested in future studies. The majority of the data needed will be collected during the development of the assessment tool. The writing up of the study will begin 1 year after the beginning of the study and conclusions will be drawn from these data. Data Analysis of Quantitative Data The extracted data is expected to be non-parametric. Descriptive statistics will describe participants' demographics and clinical characteristics, using mean, median, standard deviation, interquartile range and percentages. The Kruskal-Wallis test will be used to establish if there is a statistically significant difference between two or more groups (e.g. those without delirium, those with non-persistent delirium and those with persistent delirium). Post hoc tests will elucidate which groups differ from each other. Chi-squared tests will compare between-group distributions of proportions. Repeated measures ANOVA or Friedman's will determine changes in repeated measure assessments (e.g. full blood count, urea and electrolytes, c-reactive protein). Hierarchical logistic regression analysis, adjusting for covariates (e.g. demographics, clinical factors, infection), will ascertain the significant risk factors for delirium and provide odds ratios. Multiple comparisons will be corrected using Bonferroni's correction. Survival analysis will be utilised to determine the time to the outcomes of interest, such as persistent delirium, mortality and increase in community support. Survival curves will be compared using the log-rank test. It is expected that participants' medical records will have missing data. Missing data will be recorded to determine if there are any missing value patterns, associated with certain outcomes. To develop the assessment tool, the "regularised" regression techniques, such as LASSO or Elastic Net will be used. A scoring system will be devised which allocates an increasing number of points to risk factors that have a stronger association for predicting persistent delirium. The sensitivity and specificity of the risk assessment tool will be calculated and these characteristics will be displayed as ROC (Receiver Operator Characteristic) curves. AUC (Area Under the ROC Curve) can summarise the overall accuracy of the test and this can be computed by the trapezoidal rule. Adjusted odds ratios calculated using logistic regression will compare this study's secondary objective: associations between the management of persistent delirium and its outcomes. These findings will be assessed for their suitability for a larger study to be conducted by the Chief Investigator and these data can inform researchers about the sample size requirements for future studies.
- Interviews
Written informed consent will be sought from people with Parkinson's and their carer when they attend their routine hospital follow-up appointment. A single researcher will then meet with the participant for a one-to-one interview, lasting for about 1 hour. The interview will be conducted at either the participant's own home or another pre-arranged venue. Questions will focus on the participant's experiences of hospital, the care that they received when they returned home and the challenges that they faced in the community. It is expected that up to 20 participants in total are needed for this study, consisting of up to 10 people with Parkinson's and up to 10 carers. The interviews will begin 2 years into the study and participants will be re-consented to ensure that they still agree to the interview.
Data Analysis of Qualitative Data
The qualitative study will be analysed using thematic analysis. Phrases or expressions from the transcripts will be coded to identify interesting features. Open coding will first be used, which allows the early formation of themes and concepts. These early themes will be reviewed by comparing them to other transcripts to refine and develop recurrent themes. From this, the themes will be defined and a thematic coding frame will be produced which will include sub-themes. This process will be data-driven coding and these data will undergo open, axial and selective coding. The constant comparative method will be used to analyse data to develop a grounded theory, to explain some of the participants' behaviours and reactions to persistent delirium. To achieve this, there will simultaneous analysing and coding of data; each new set of data will be compared to previous extracts, new codes and themes will be added as necessary whilst comparing participants' responses, so that the themes are refined. Integration of these findings will begin the development of an explanatory model. Findings will be reported as recommended by COREQ (consolidated criteria for reporting qualitative research) guidance. The Chief Investigator will be the main data coder, with assistance from Co-Investigators.
- Conditions
- Parkinson Disease, Delirium in Old Age
- Being tested
- Delirium (exposure)
- Keywords
- Parkinson's, Delirium, Older
- Medical subject headings
- Parkinson Disease, Delirium
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Delirium (exposure)Other
No interventions.
| Study group | Role | What they receive |
|---|---|---|
| Persistent delirium | People with Parkinson's who have experienced persistent delirium (delirium lasting for ≥14 days) and will also be invited to interview. Receives: Other: Delirium (exposure) | |
| Non-persistent delirium | People with Parkinson's who have experienced non-persistent delirium (delirium lasting <14 days). Receives: Other: Delirium (exposure) | |
| No delirium (Control group) | People with Parkinson's who have never experienced delirium | |
| Carers for Qualitative Interview | Carers of people with Parkinson's who have consented to being interviewed. Receives: Other: Delirium (exposure) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence and prevalence of delirium in older people with Parkinson's, measured by the DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition).
DSM-V (Diagnostic and Statistical Manual of Mental Disorders 5th edition) will be used to confirm the diagnosis of delirium.
Measured: Time frame: measured when the participant has previously encountered healthcare professionals during 2015-2019.
The duration of delirium will be measured in days.
Once delirium is confirmed by the DSM-V criteria, then the number of days that participants are affected by delirium will be inferred from medical notes.
Measured: Time frame: measured when the participant has previously encountered healthcare professionals during 2015-2019.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2022
- Study start6 Feb 2022
- Primary completion30 Aug 2025 (estimated)
- Study completion30 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (20)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 217 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Newcastle University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- William Lee, MB/BS, Principal investigator, Airedale Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05437458
- Sponsor's protocol ID
- 293560
- Acronym
- PARADIGM
- Status last verified
- May 2023
- First submitted
- 4 Apr 2022
- Last updated
- 1 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: To occur after the PARADIGM has published its study findings.
Publications
AMERICAN PSYCHIATRIC ASSOCIATION 2013. Delirium. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC.
Billings J, Mijanovich T. Improving the management of care for high-cost Medicaid patients. Health Aff (Millwood). 2007 Nov-Dec;26(6):1643-54. doi: 10.1377/hlthaff.26.6.1643.
PubMed 17978384BRAUN, V. & CLARKE, V. 2006. Using thematic analysis in psychology. Qualitative research in psychology, 3, 77-101.
Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age Ageing. 2009 Jan;38(1):19-26. doi: 10.1093/ageing/afn253. Epub 2008 Nov 18.
PubMed 19017678Davis DH, Muniz Terrera G, Keage H, Rahkonen T, Oinas M, Matthews FE, Cunningham C, Polvikoski T, Sulkava R, MacLullich AM, Brayne C. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain. 2012 Sep;135(Pt 9):2809-16. doi: 10.1093/brain/aws190. Epub 2012 Aug 9.
PubMed 22879644Kakuma R, du Fort GG, Arsenault L, Perrault A, Platt RW, Monette J, Moride Y, Wolfson C. Delirium in older emergency department patients discharged home: effect on survival. J Am Geriatr Soc. 2003 Apr;51(4):443-50. doi: 10.1046/j.1532-5415.2003.51151.x.
PubMed 12657062Kouli A, Torsney KM, Kuan WL. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 1. Available from http://www.ncbi.nlm.nih.gov/books/NBK536722/
PubMed 30702842Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2019 Jul;64:29-39. doi: 10.1016/j.parkreldis.2018.09.025. Epub 2018 Sep 26.
PubMed 30279060Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):324-30. doi: 10.1136/jnnp-2014-307822. Epub 2014 May 29.
PubMed 24876185MEHRA, A., SURENDRAN, I., SURI, V. & GROVER, S. 2014. Missed diagnosis-persistent delirium. Journal of Geriatric Mental Health, 1, 118.
Read J, Cable S, Lofqvist C, Iwarsson S, Bartl G, Schrag A. Experiences of health services and unmet care needs of people with late-stage Parkinson's in England: A qualitative study. PLoS One. 2019 Dec 30;14(12):e0226916. doi: 10.1371/journal.pone.0226916. eCollection 2019.
PubMed 31887175Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006 Jul;35(4):350-64. doi: 10.1093/ageing/afl005. Epub 2006 Apr 28.
PubMed 16648149ROSNER, B. 2015. Fundamentals of biostatistics, Cengage learning.
TAYLOR, S. J. & BOGDAN, R. 1984. Introduction to qualitative research methods: The search for meanings, Wiley-Interscience.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007 Dec;19(6):349-57. doi: 10.1093/intqhc/mzm042. Epub 2007 Sep 14.
PubMed 17872937
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Parkinson's Disease: Risk Assessment of Persistent Delirium and Its Management
- ClinicalTrials.gov ID
- NCT05437458
- Acronym / sponsor ID
- PARADIGM / 293560
- Conditions
- Parkinson Disease, Delirium in Old Age
- Keywords
- Parkinson's, Delirium, Older
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 217 participants (estimated)
- Lead sponsor
- Newcastle UniversityUniversity, hospital or other
- Study start
- 6 Feb 2022 (actual)
- Primary completion
- 30 Aug 2025 (estimated)
- Study completion
- 30 Sep 2025 (estimated)
- First posted
- 29 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: delirium describes the change in people's behaviour and thinking when they are unwell. People with delirium may appear confused, have difficulty with organisation and can be different to their usual personality. Older people with Parkinson's are particularly susceptible to persistent delirium, which can last over 14 days. They are more likely to need increased community support and they have a greater risk of death and dementia.
However, there is limited research for people with Parkinson's on how to effectively manage persistent delirium and how to identify those at risk of persistent delirium. Community support may not sufficiently support the care needs of people with Parkinson's, and this is expected to be more detrimental for people also affected by persistent delirium
Study Design: retrospective case note review with qualitative interviews.
Study participants: older people (≥65 years old) with Parkinson's disease, previously affected by either persistent delirium or another form of delirium (e.g. hyperactive, hypoactive, mixed). 207 participants with Parkinson's for quantitative data collection. The qualitative study will include up to 10 participants with Parkinson's from the quantitative part of this study. An additional maximum of 10 more carers for people with Parkinson's may also be interviewed.
Research Aims:
- To develop and estimate the assessment tool's sensitivity and specificity to predict persistent delirium in older people with Parkinson's in the outpatient setting. Persistent delirium in this study will be initially defined as a delirium lasting ≥14 days. An associated secondary objective will be to develop a scoring system that allocates an increasing number of points to risk factors that have a stronger association for predicting delirium.
- To evaluate the management strategies used for persistent delirium.
- To determine what are the community care needs for people recovering from persistent delirium.
Detailed description
Background and Rationale Parkinson's disease is the second most common neurodegenerative condition. Delirium is an acute neuropsychiatric syndrome characterised by an altered level of consciousness, confusion and impaired attention. Usually, delirium is transient if the aetiological factors are corrected or if its effects are minimised by medical treatment. Delirium is potentially preventable in 30-40% of cases, but delirium can result in increased mortality and an increased risk of dementia.
Persistent delirium is when delirium continues to affect patients over weeks to months. However, the exact duration for delirium to be defined as being persistent remains controversial. Previous studies have reported the duration of persistent delirium to be between 7 days to >4 weeks. Persistent delirium in this study will be defined as delirium lasting ≥14 days, which is the average reported by the previous studies. Delirium in older people at the point of hospital discharge is associated with worse outcomes regarding function, cognition, mortality and are more likely to need nursing home placement.
People with Parkinson's could be five times more likely to develop delirium and often delirium in Parkinson's is under-recognised in secondary care.
The use of risk stratification of delirium in people with Parkinson's could highlight the most vulnerable patients so that preventive care can be implemented to minimise their risk of adverse outcomes and complications.
Currently, management strategies for delirium in Parkinson's disease are predominantly based on expert opinion and there is a need for research to determine what are the optimal management strategies for this patient group. Moreover, there are concerns that current community support services do not adequately address the psychosocial issues in older people with advanced Parkinson's disease, which may provide an even greater challenge for patients recovering from persistent delirium.
In summary, older people with Parkinson's are particularly susceptible to delirium, but there is also a paucity of research in this area, which needs to be urgently addressed, to not only prevent the adverse outcomes at an individual level but also the detrimental socio-economic impacts on the wider community.
Participant Recruitment
Eligible potential participants will be invited to the study by their usual medical team during an outpatient Parkinson's clinic at a rural, district general hospital. Eligible potential participants with their permission will be contacted by researchers. Carers of people with Parkinson's will be invited to a qualitative interview. Participants will be recruited consecutively in the order that consent forms were completed till the target sample size has been achieved for the quantitative part of the study. For the qualitative part of the study, recruitment will cease once data saturation has been reached.
Methods
There are 3 main parts to this study:
- Development and testing of an assessment tool for persistent delirium in people with Parkinson's: Participants will be recruited from outpatient clinics for people with Parkinson's this may take up to 8 months. Initially, the potential participant's usual doctor will invite them to take part in the study, before the research team goes through the details of the study with the potential participant. Written informed consent will be needed. If the potential participant cannot consent for themselves, then a consultee will be contacted. A consultee is someone that is well known to the potential participant and is willing to advise on whether the potential participant, should take part in the study. In tandem with participant recruitment for at least 14 months, there will be data collection from medical records. Medical records will be reviewed to identify the characteristics and events that have affected people who then go on to develop persistent delirium. Participants' characteristics that will be analysed will be broadly related to their general level of physical fitness, the severity of their Parkinson's disease, visual or hearing difficulties and any conditions affecting their mind, such as dementia. Events that the medical notes will be checked for include: the medical care, blood tests and imaging that the participant received, any complications during their hospital stay and the support that they received in the community. Participants will be divided into 3 groups: those with persistent delirium, which is where participants become unwell, which has led to the participant becoming confused or have changes in their behaviour for 14 days or more. Another group with non-persistent delirium, this is when the delirium has lasted less than 14 days and a control group who have not had delirium at all. The Chief Investigator will write a summary of each participant but identifiable details will be excluded. These summaries will be reviewed by at least one other medical specialist involved in the care of older people, to double-check that the study findings are as accurate as possible. Potentially, another medical colleague may be required if there is any initial disagreement between specialists. To further confirm the accuracy of the findings, healthcare staff entries in the notes and information collected from relatives/carers can also be used. 8 months will be needed to develop and test the assessment tool. This will be done by using statistical methods, such as logistic regression to determine which of these factors are most strongly linked to persistent delirium. A scoring system can be developed, which allocates an increasing number of points to participants with a risk factor that is more strongly linked to persistent delirium. The accuracy of the tool will be determined by its ability to detect people with delirium (sensitivity) and its ability to detect people without delirium (specificity). It is estimated that 207 participants will be required. This is assuming that persistent delirium is present in approximately 20% of patients. The estimate of persistent delirium is based on local audit data.
- Development of a management plan From the information collected in 1), there will be a review of the care that a participant received to identify factors that helped and hindered their recovery from delirium. This information will allow the Chief Investigator to begin to develop a care plan, which can then be tested in future studies. The majority of the data needed will be collected during the development of the assessment tool. The writing up of the study will begin 1 year after the beginning of the study and conclusions will be drawn from these data. Data Analysis of Quantitative Data The extracted data is expected to be non-parametric. Descriptive statistics will describe participants' demographics and clinical characteristics, using mean, median, standard deviation, interquartile range and percentages. The Kruskal-Wallis test will be used to establish if there is a statistically significant difference between two or more groups (e.g. those without delirium, those with non-persistent delirium and those with persistent delirium). Post hoc tests will elucidate which groups differ from each other. Chi-squared tests will compare between-group distributions of proportions. Repeated measures ANOVA or Friedman's will determine changes in repeated measure assessments (e.g. full blood count, urea and electrolytes, c-reactive protein). Hierarchical logistic regression analysis, adjusting for covariates (e.g. demographics, clinical factors, infection), will ascertain the significant risk factors for delirium and provide odds ratios. Multiple comparisons will be corrected using Bonferroni's correction. Survival analysis will be utilised to determine the time to the outcomes of interest, such as persistent delirium, mortality and increase in community support. Survival curves will be compared using the log-rank test. It is expected that participants' medical records will have missing data. Missing data will be recorded to determine if there are any missing value patterns, associated with certain outcomes. To develop the assessment tool, the "regularised" regression techniques, such as LASSO or Elastic Net will be used. A scoring system will be devised which allocates an increasing number of points to risk factors that have a stronger association for predicting persistent delirium. The sensitivity and specificity of the risk assessment tool will be calculated and these characteristics will be displayed as ROC (Receiver Operator Characteristic) curves. AUC (Area Under the ROC Curve) can summarise the overall accuracy of the test and this can be computed by the trapezoidal rule. Adjusted odds ratios calculated using logistic regression will compare this study's secondary objective: associations between the management of persistent delirium and its outcomes. These findings will be assessed for their suitability for a larger study to be conducted by the Chief Investigator and these data can inform researchers about the sample size requirements for future studies.
- Interviews
Written informed consent will be sought from people with Parkinson's and their carer when they attend their routine hospital follow-up appointment. A single researcher will then meet with the participant for a one-to-one interview, lasting for about 1 hour. The interview will be conducted at either the participant's own home or another pre-arranged venue. Questions will focus on the participant's experiences of hospital, the care that they received when they returned home and the challenges that they faced in the community. It is expected that up to 20 participants in total are needed for this study, consisting of up to 10 people with Parkinson's and up to 10 carers. The interviews will begin 2 years into the study and participants will be re-consented to ensure that they still agree to the interview.
Data Analysis of Qualitative Data
The qualitative study will be analysed using thematic analysis. Phrases or expressions from the transcripts will be coded to identify interesting features. Open coding will first be used, which allows the early formation of themes and concepts. These early themes will be reviewed by comparing them to other transcripts to refine and develop recurrent themes. From this, the themes will be defined and a thematic coding frame will be produced which will include sub-themes. This process will be data-driven coding and these data will undergo open, axial and selective coding. The constant comparative method will be used to analyse data to develop a grounded theory, to explain some of the participants' behaviours and reactions to persistent delirium. To achieve this, there will simultaneous analysing and coding of data; each new set of data will be compared to previous extracts, new codes and themes will be added as necessary whilst comparing participants' responses, so that the themes are refined. Integration of these findings will begin the development of an explanatory model. Findings will be reported as recommended by COREQ (consolidated criteria for reporting qualitative research) guidance. The Chief Investigator will be the main data coder, with assistance from Co-Investigators.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Persistent delirium | – | Other: Delirium (exposure)People with Parkinson's who have experienced persistent delirium (delirium lasting for ≥14 days) and will also be invited to interview. |
| Non-persistent delirium | – | Other: Delirium (exposure)People with Parkinson's who have experienced non-persistent delirium (delirium lasting <14 days). |
| No delirium (Control group) | – | –People with Parkinson's who have never experienced delirium |
| Carers for Qualitative Interview | – | Other: Delirium (exposure)Carers of people with Parkinson's who have consented to being interviewed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 1. People aged 65 years or older in 2015, with a diagnosis of idiopathic Parkinson's, who attend the outpatient clinic at Airedale Hospital and have had a hospital admission of at least 24 hours during 2015-2019. 2. A carer (aged 18 years and older) for a person with Parkinson's, who has experienced persistent delirium.
Key inclusion criteria (10 listed)
- Participants must be aged at least 65 years old in 2015.
- Participants must have a diagnosis of idiopathic Parkinson's disease using Queen's Square Brain Bank criteria (32) diagnosed by a movement disorders expert.
- Admitted patients must have stayed in hospital >24 hours for at least one hospital admission.
- Participants must have had previous admissions/attendance to the hospital between 2015-2019.
- An appropriate consultee must be available and willing to be involved in this study for potential participants without the mental capacity to consent to the extraction of information from their medical records.
Key exclusion criteria (14 listed)
- Aged less than 65 years old in 2015.
- Diagnosed with drug-induced parkinsonism, vascular parkinsonism, atypical Parkinsonian disorder (e.g. progressive supranuclear palsy, multiple systems atrophy, corticobasal syndrome) or dementia (e.g. dementia with Lewy bodies, vascular dementia, Alzheimer's disease).
- Potential participants will be excluded from the interview if they cannot communicate verbally or cannot read/write in English.
- The potential participant's medical records are incomplete and no alternate strategies are appropriate to account for the missing data, without introducing significant study bias or inaccuracy in statistical findings. Criteria for when the medical records will be excluded in the analysis will be:
- 1. There is uncertainty regarding the identity of the medical records. 2. Documentation for the admission of interest is missing to the extent that researchers are unable to extract the relevant data required for the aims of this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Delirium (exposure)No interventions. | Other | Carers for Qualitative Interview, Non-persistent delirium, Persistent delirium |
Primary outcome
The incidence and prevalence of delirium in older people with Parkinson's, measured by the DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition).
Time frame: Time frame: measured when the participant has previously encountered healthcare professionals during 2015-2019.
DSM-V (Diagnostic and Statistical Manual of Mental Disorders 5th edition) will be used to confirm the diagnosis of delirium.
The duration of delirium will be measured in days.
Time frame: Time frame: measured when the participant has previously encountered healthcare professionals during 2015-2019.
Once delirium is confirmed by the DSM-V criteria, then the number of days that participants are affected by delirium will be inferred from medical notes.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2023.
- BackgroundAMERICAN PSYCHIATRIC ASSOCIATION 2013. Delirium. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC.
- Background: PubMed 17978384Billings J, Mijanovich T. Improving the management of care for high-cost Medicaid patients. Health Aff (Millwood). 2007 Nov-Dec;26(6):1643-54. doi: 10.1377/hlthaff.26.6.1643.
- BackgroundBRAUN, V. & CLARKE, V. 2006. Using thematic analysis in psychology. Qualitative research in psychology, 3, 77-101.
- Background: PubMed 19017678Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age Ageing. 2009 Jan;38(1):19-26. doi: 10.1093/ageing/afn253. Epub 2008 Nov 18.
- Background: PubMed 22879644Davis DH, Muniz Terrera G, Keage H, Rahkonen T, Oinas M, Matthews FE, Cunningham C, Polvikoski T, Sulkava R, MacLullich AM, Brayne C. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain. 2012 Sep;135(Pt 9):2809-16. doi: 10.1093/brain/aws190. Epub 2012 Aug 9.
- Background: PubMed 12657062Kakuma R, du Fort GG, Arsenault L, Perrault A, Platt RW, Monette J, Moride Y, Wolfson C. Delirium in older emergency department patients discharged home: effect on survival. J Am Geriatr Soc. 2003 Apr;51(4):443-50. doi: 10.1046/j.1532-5415.2003.51151.x.
- Background: PubMed 30702842Kouli A, Torsney KM, Kuan WL. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 1. Available from http://www.ncbi.nlm.nih.gov/books/NBK536722/
- Background: PubMed 30279060Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2019 Jul;64:29-39. doi: 10.1016/j.parkreldis.2018.09.025. Epub 2018 Sep 26.
- Background: PubMed 24876185Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):324-30. doi: 10.1136/jnnp-2014-307822. Epub 2014 May 29.
- BackgroundMEHRA, A., SURENDRAN, I., SURI, V. & GROVER, S. 2014. Missed diagnosis-persistent delirium. Journal of Geriatric Mental Health, 1, 118.
- Background: PubMed 31887175Read J, Cable S, Lofqvist C, Iwarsson S, Bartl G, Schrag A. Experiences of health services and unmet care needs of people with late-stage Parkinson's in England: A qualitative study. PLoS One. 2019 Dec 30;14(12):e0226916. doi: 10.1371/journal.pone.0226916. eCollection 2019.
- Background: PubMed 16648149Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006 Jul;35(4):350-64. doi: 10.1093/ageing/afl005. Epub 2006 Apr 28.
- Individual participant dataSharing planned: Yes. To occur after the PARADIGM has published its study findings.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William Lee, MB/BS principal investigator
Airedale Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease and Delirium in Old Age, run by Newcastle University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact William Lee, MB/BS (01535 652511 ext. 5086, william.lee4@nhs.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence and prevalence of delirium in older people with Parkinson's, measured by the DSM-V criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition). (time frame: Time frame: measured when the participant has previously encountered healthcare professionals during 2015-2019.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05437458, which also lists 20 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2023.